| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;94:906-910.)
© 1996 American Heart Association, Inc.
Articles |
Differential Dose-Response to Oral Xemilofiban After Antecedent Intravenous Abciximab
Administration for Complex Coronary Intervention
the Departments of Cardiology and Internal Medicine, University of Cincinnati (Ohio) College of Medicine (D.J.K., J.P.R.); the Division of Cardiology, Baylor College of Medicine, Houston, Tex (N.S.K.); the Carl and Edyth Lindner Center for Clinical Cardiovascular Research at the Health Alliance of Greater Cincinnati (Ohio) (N.A.H., L.C.A.); and G.D. Searle & Co, Skokie, Ill (G.H., S.M., R.J.A.).
Correspondence to Dean J. Kereiakes, MD, The Carl and Edyth Lindner Center for Clinical Cardiovascular Research, 2123 Auburn Ave, Suite 424, Cincinnati, OH 45219.
Background Placebo-controlled randomized trials of parenteral platelet glycoprotein (GP) IIb/IIIa receptor antagonists have demonstrated reduced ischemic complications of coronary angioplasty. Orally active GP IIb/IIIa blockers are being developed to allow more sustained receptor antagonism with potential for long-term secondary prevention. Sequential therapy with abciximab followed by an oral IIb/IIIa antagonist has not previously been reported. The clinical safety and pharmacodynamics of a sequential therapeutic strategy are unknown.
Methods and Results Of 74 consecutive patients enrolled in a placebo-controlled, dose-ranging pharmacokinetic/pharmacodynamic study of xemilofiban, a new oral nonpeptide GP IIb/IIIa antagonist, after elective intracoronary stent placement, 17 patients received abciximab during stent deployment as a weight-adjusted intravenous bolus and 12-hour infusion at the discretion of the investigator. Ex vivo platelet aggregation in response to 20 µmol/L ADP and 4 µg/mL collagen was measured over time after the first dose of either xemilofiban (5, 10, 15, or 20 mg) or placebo (ticlopidine) administered 8 to 18 hours after termination of abciximab and again after 1 week of twice-daily oral administration of study drug. At baseline, patients who had received abciximab had lower platelet aggregation in response to both agonists (P<.001). A significant dose-response relationship to xemilofiban was observed. Patients who had received abciximab had lower ADP-induced (P
.010) and collagen-induced (P.029) platelet aggregation after xemilofiban. This pharmacodynamic interaction was no longer evident at 1 week. No significant clinical bleeding events or blood product transfusions were observed in this trial.
Conclusions Both the magnitude and the duration of pharmacodynamic response to xemilofiban were enhanced by prior abciximab treatment. The potentiated pharmacodynamic response was not evident after 1 week. This observation has implications for the safety and efficacy of sequential parenteral-oral GP IIb/IIIa blockade therapy and may be useful in deriving dose regimens for orally administered compounds.
Key Words: aggregation inhibitors • platelets • glycoproteins
This article has been cited by other articles:
 |
|
 |
|
  I. Mahmood and M. D. Green Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies J. Clin. Pharmacol., December 1, 2007; 47(12): 1540 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. I. Lev, J. I. Osende, M. F. Richard, J. A. Robbins, J. A. Delfin, O. Rodriguez, S. K. Sharma, T. Jayasundera, J. J. Badimon, and J. D. Marmur Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function J. Am. Coll. Cardiol., March 1, 2001; 37(3): 847 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Chew, D. L. Bhatt, S. Sapp, and E. J. Topol Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists : A Meta-Analysis of Phase III Multicenter Randomized Trials Circulation, January 16, 2001; 103(2): 201 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Chew and D. J. Moliterno A critical appraisal of platelet glycoprotein IIb/IIIa inhibition J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2028 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Quinn, A. Deering, M. Stewart, D. Cox, B. Foley, and D. Fitzgerald Quantifying GPIIb/IIIa Receptor Binding Using 2 Monoclonal Antibodies : Discriminating Abciximab and Small Molecular Weight Antagonists Circulation, May 4, 1999; 99(17): 2231 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Ault, C. P. Cannon, J. Mitchell, J. McCahan, R. P. Tracy, W. F. Novotny, J. D. Reimann, and E. Braunwald Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial J. Am. Coll. Cardiol., March 1, 1999; 33(3): 634 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Smith, S. R. Steinhubl, A. M. Lincoff, J. C. Coleman, T. T. Lee, R. S. Hillman, and B. S. Coller Rapid Platelet-Function Assay : An Automated and Quantitative Cartridge-Based Method Circulation, February 9, 1999; 99(5): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Madan, S. D. Berkowitz, and J. E. Tcheng Glycoprotein IIb/IIIa Integrin Blockade Circulation, December 8, 1998; 98(23): 2629 - 2635. [Full Text] [PDF]
|
|
|
|
|
|
R.F. Storey, R.G. Wilcox, and S. Heptinstall Differential Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Microaggregate and Macroaggregate Formation and Effect of Anticoagulant on Antagonist Potency : Implications for Assay Methodology and Comparison of Different Antagonists Circulation, October 20, 1998; 98(16): 1616 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, N. S. Kleiman, J. J. Ferguson, A. R. Z. Masud, T. M. Broderick, C. W. Abbottsmith, J. P. Runyon, L. C. Anderson, R. J. Anders, R. J. Dreiling, et al. Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban : Results of a Multicenter, Placebo-Controlled, Randomized Trial Circulation, September 29, 1998; 98(13): 1268 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Vorchheimer and V. Fuster Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonists: The Present Challenge Is Safety Circulation, February 3, 1998; 97(4): 312 - 314. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, C. H. McCabe, S. Borzak, T. D. Henry, M. D. Tischler, H. S. Mueller, R. Feldman, S. T. Palmeri, K. Ault, S. A. Hamilton, et al. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome : Results of the TIMI 12 Trial Circulation, February 3, 1998; 97(4): 340 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Coller Monitoring Platelet GP IIb/IIIa Antagonist Therapy Circulation, January 13, 1998; 97(1): 5 - 9. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, N. Kleiman, J. J. Ferguson, J. P. Runyon, T. M. Broderick, N. A. Higby, L. H. Martin, G. Hantsbarger, S. McDonald, and R. J. Anders Sustained Platelet Glycoprotein IIb/IIIa Blockade With Oral Xemilofiban in 170 Patients After Coronary Stent Deployment Circulation, August 19, 1997; 96(4): 1117 - 1121. [Abstract] [Full Text]
|
|
|
|
|
|
J. T. Willerson Inhibitors of Platelet Glycoprotein IIb/IIIa Receptors: Will They Be Useful When Given Chronically? Circulation, September 1, 1996; 94(5): 866 - 868. [Full Text]
|
|